| 6th Feb 2024 7:05 am |
RNS |
Shingrix 18+ at risk China filing review accepted |
| 6th Feb 2024 7:00 am |
RNS |
GSK presents positive DREAMM-7 phase III data |
| 1st Feb 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 1st Feb 2024 3:00 pm |
RNS |
Total Voting Rights |
| 1st Feb 2024 7:00 am |
RNS |
Statement: Zantac (ranitidine) litigation |
| 31st Jan 2024 7:00 am |
RNS |
Final Results |
| 29th Jan 2024 7:05 am |
RNS |
EMA accepts Arexvy filing for adults 50-59 at risk |
| 29th Jan 2024 7:00 am |
RNS |
European Commission authorises Omjjara in the EU |
| 19th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 18th Jan 2024 5:00 pm |
RNS |
Holding(s) in Company |
| 17th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 17th Jan 2024 7:00 am |
RNS |
GSK completes sale of shares in Haleon plc |
| 16th Jan 2024 4:40 pm |
RNS |
GSK announces intention to sell shares in Haleon |
| 16th Jan 2024 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 10th Jan 2024 7:00 am |
RNS |
Nucala approved in China for use in severe asthma |
| 9th Jan 2024 7:00 am |
RNS |
GSK enters agreement to acquire Aiolos Bio |
| 2nd Jan 2024 3:00 pm |
RNS |
Total Voting Rights |
| 21st Dec 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 20th Dec 2023 4:44 pm |
RNS |
Publication of EMTN Suppl.Prospcts |
| 18th Dec 2023 7:00 am |
RNS |
Jemperli plus Zejula Trial Meets Endpoint |
| 13th Dec 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 12th Dec 2023 7:00 am |
RNS |
Japan accepts Arexvy filing for at risk adults |
| 11th Dec 2023 7:00 am |
RNS |
Jemperli plus chemotherapy EU authorisation |
| 4th Dec 2023 3:02 pm |
RNS |
GSK publishes provisional 2024 dividend dates |
| 1st Dec 2023 3:00 pm |
RNS |
Total Voting Rights |
| 30th Nov 2023 9:00 am |
RNS |
Block Listing Application |
| 29th Nov 2023 3:23 pm |
RNS |
Holding(s) in Company |
| 27th Nov 2023 7:00 am |
RNS |
GSK announces positive DREAMM-7 headline results |
| 21st Nov 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 15th Nov 2023 3:00 pm |
RNS |
Block listing Interim Review |
| 13th Nov 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 13th Nov 2023 7:00 am |
RNS |
GSK receives positive CHMP opinion for momelotinib |
| 1st Nov 2023 3:00 pm |
RNS |
Total Voting Rights |
| 1st Nov 2023 7:00 am |
RNS |
3rd Quarter Results |
| 30th Oct 2023 7:00 am |
RNS |
Jemperli trial meets overall survival endpoint |
| 26th Oct 2023 7:00 am |
RNS |
NMPA approves Vocabria+Rekambys in China |
| 25th Oct 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 25th Oct 2023 7:00 am |
RNS |
New data for Arexvy, GSK’s RSV vaccine |
| 20th Oct 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
| 18th Oct 2023 3:30 pm |
RNS |
Director/PDMR Shareholding |
